Impact of frequency and duration of freeze-dried inactivated tissue culture hepatitis A vaccine (Aimmugen®) vaccination on antibody titers; a japanese cross-sectional study

Maki, Yohei; Edo, Naoki; Mizuguchi, Makoto; Ikeda, Mikihito; Kitano, Masato; Kitagami, Etsuko; Osa, Morichika; Yamamoto, Shotaro; Ogawa, Takunori; Nakamura, Takahiro; Kawana, Akihiko; Kimizuka, Yoshifumi

doi:10.1016/j.vaccine.2023.08.030

Cited by 1 publication

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Japan, the Pharmaceuticals and Medical Devices Agency has granted approval exclusively to an inactivated aluminum-free 14 hepatitis A vaccine. 173,236,237 However, this vaccine is not included in the coverage provided by the Japanese National Health Insurance System. Comprehensive information regarding the specific methods of administration, efficacy, and potential adverse events associated with the hepatitis A vaccine can be obtained from sources.…”

Section: Future Researchmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan

Kanda,

Sasaki‐Tanaka,

Ishii

et al. 2023

Hepatology Research

View full text Add to dashboard Cite

In 2018, there was a hepatitis A outbreak in Japan, and hepatitis A virus (HAV) infection is considered a sexually transmitted disease. In general, patients with hepatitis A should be given attention, and this disease should be prevented more than ever. The Japan Agency for Medical Research and Development (AMED) Hepatitis A and E viruses (HAV and HEV) Study Group has worked on the project to create “Recent Advances in Hepatitis A Virus (HAV) Research and Clinical Practice Guidelines for HAV Infection in Japan”. The group consists of expert hepatologists and virologists who gathered at virtual meeting on August 5, 2023. Data about the pathogenesis, infection routes, diagnosis, complications, several factors for the severities, vaccination, and current and future treatments for hepatitis A were discussed and debated for a draft version. The participants assessed the quality of cited studies. The finalized recommendations are presented in this review. The recent advances in HAV research and clinical practice for HAV infection in Japan, have been reviewed by the AMED HAV and HEV Study Group.

show abstract

Section: Future Researchmentioning

confidence: 99%

“…Comprehensive information regarding the specific methods of administration, efficacy, and potential adverse events associated with the hepatitis A vaccine can be obtained from sources. 173,236,237…”

Section: Future Researchmentioning

confidence: 99%